Related Experiment Video

Updated: Jul 2, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Biologic therapies for advanced pancreatic cancer

Aiwu Ruth He1, Andreas Peter Lindenberg, John Lindsay Marshall

  • 1Department of Medicine, Division of Hematology/Oncology, Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW Washington, DC 20007, USA. aiwu.r.he@gunet.georgetown.edu

Expert Review of Anticancer Therapy
|August 14, 2008
PubMed

Insights

Metastatic pancreatic cancer has a poor prognosis. While current targeted therapies show limited success, ongoing research into novel inhibitors and patient selection strategies offers hope for improved pancreatic cancer treatments.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Metastatic pancreatic cancer is aggressive with poor patient prognosis due to limited effective therapies.
  • The disease is characterized by chromosomal instability, including translocations and deletions.
  • Upregulated Epidermal Growth Factor (EGF) signaling and Kirsten Rat Sarcoma (K-RAS) mutations are common in pancreatic cancers.

Purpose of the Study:

  • To review the current landscape of targeted therapy inhibitors evaluated in clinical trials for pancreatic cancer.
  • To summarize the experience and knowledge gained from these trials.
  • To discuss future directions for improving pancreatic cancer treatment.

Main Methods:

  • Review of clinical trial data and scientific literature on targeted therapies for pancreatic cancer.
  • Analysis of therapeutic targets including EGF receptor, K-RAS, RAF, MEK, mTOR, Vascular Endothelial Growth Factor (VEGF), and Platelet-Derived Growth Factor (PDGF).

Main Results:

  • Targeted inhibitors have shown limited significant activity in the majority of pancreatic cancer patients.
  • Clinical trials have generated substantial experience and knowledge regarding inhibitor efficacy and challenges.
  • Patient selection and combination strategies are critical for therapeutic success.

Conclusions:

  • Despite current limitations, advancements in inhibitor development and patient stratification hold promise for future pancreatic cancer therapies.
  • Optimizing inhibitor combinations and refining patient selection criteria are key to improving outcomes.
  • A better therapeutic approach for pancreatic cancer is anticipated with continued research and clinical development.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...